Actively Recruiting
Studying the Role of Sclerostin Protein in Bone Disease for Adults with Mastocytosis
Led by Medical University of Lublin · Updated on 2024-06-03
50
Participants Needed
1
Research Sites
139 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying mastocytosis, a rare condition marked by the buildup of abnormal mast cells in organs such as the skin, bone marrow, and liver. This condition often affects the bones, with around 70% of people with systemic mastocytosis experiencing bone involvement. The study aims to understand the role of a bone protein called sclerostin in causing bone changes related to mastocytosis. The research involves adult patients with different types of mastocytosis, including aggressive systemic, systemic with related blood diseases, smouldering systemic, indolent systemic, and cutaneous mastocytosis, along with a group of healthy volunteers. Researchers measure levels of sclerostin and its gene expression in blood plasma and mast cell cultures using PCR and ELISA methods. Bone changes are assessed with low-dose CT scans. Participants will undergo blood tests for sclerostin levels and gene expression, along with imaging to evaluate bone lesions. These findings will be compared with clinical and laboratory data to understand bone disease progression in mastocytosis. The main outcomes measured include sclerostin levels and the size of bone lesions over one year. The study is sponsored by the Medical University of Lublin and includes healthy volunteers for comparison.
CONDITIONS
Brief Title
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Research Team
A
Aneta Szudy-Szczyrek, MD., PhD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here